-
11.发明授权公开(公告)号：US09745379B2
公开(公告)日：2017-08-29
申请号：US14949424
申请日：2015-11-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/00 , C07H21/00 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/48569 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6872 , G01N2333/70578
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
12.发明授权Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof 有权抗糖皮质激素诱导的肿瘤坏死因子受体（GITR）的抗体及其用途公开(公告)号：US09228016B2
公开(公告)日：2016-01-05
申请号：US14732082
申请日：2015-06-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/00 , C07H21/00 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/48569 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6872 , G01N2333/70578
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Abstract translation: 本文提供了结合糖皮质激素诱导型TNF受体（GITR）的抗体或其抗原结合部分。 还提供了这些蛋白质在治疗应用中的用途，例如在癌症的治疗中。 还提供了产生抗体的细胞，编码抗体的重链和/或轻链可变区的多核苷酸，以及包含编码抗体的重链和/或轻链可变区的多核苷酸的载体。
-
公开(公告)号：US11408889B2
公开(公告)日：2022-08-09
申请号：US16870006
申请日：2020-05-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xi-Tao Wang , Olufemi A. Adelakun , Anne C. Lewin , Alan J. Korman , Mark J. Selby , Changyu Wang , Haichun Huang , Karla A. Henning , Nils Lonberg , Mohan Srinivasan , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Susan Chien-Szu Wong , Huiming Li
IPC: G01N33/566 , G01N33/574 , C07K16/28
Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
公开(公告)号：US20200079848A1
公开(公告)日：2020-03-12
申请号：US16506754
申请日：2019-07-09
Inventor： Xiao Min Schebye , Diana Yuhui Chen , Andrew Rankin , Xiaodi Deng , Joseph Toth , Linda Liang , Michelle Minhua Han , Christine Bee , Hong-An Truong , Mark J. Selby , Nils Lonberg , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Alan J. Korman
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06 , G01N33/577 , G01N33/563 , A61P35/00
Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
-
公开(公告)号：US20190062456A1
公开(公告)日：2019-02-28
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , G01N33/573 , A61K45/06 , C07K16/28 , C07K16/30 , A61K39/395 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
Patent Agency Ranking
公开(公告)号：US12049503B2
公开(公告)日：2024-07-30
申请号：US18451990
申请日：2023-08-18
Applicant: Bristol-Myers Squibb Company
Inventor： James Novotny , Nils Lonberg , Cyrus Hedvat , Raphael Clynes , Darren Locke , John P. Cogswell , Jeffrey Jackson , Christopher Harbison , Robin Edwards
IPC: C07K16/28 , A61K39/00 , A61P35/00 , G01N33/574
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2818 , G01N33/574 , A61K2039/507
Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
-
17.发明授权公开(公告)号：US11802162B2
公开(公告)日：2023-10-31
申请号：US16663583
申请日：2019-10-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/28 , A61K47/68 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , C07K16/2818 , C07K16/2863 , G01N33/57492 , G01N33/6863 , G01N33/6872 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N2333/70578 , G01N2333/7151
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20230051701A1
公开(公告)日：2023-02-16
申请号：US17737403
申请日：2022-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , C07K16/28 , C07K16/30 , A61K39/395 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US11274152B2
公开(公告)日：2022-03-15
申请号：US17018241
申请日：2020-09-11
Applicant: Bristol-Myers Squibb Company
Inventor： Alan J. Korman , Nils Lonberg , David J. Fontana , Andres A. Gutierrez , Mark J. Selby , Katherine Lewis
Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
-
公开(公告)号：US10690674B2
公开(公告)日：2020-06-23
申请号：US15578874
申请日：2016-06-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xi-Tao Wang , Olufemi A. Adelakun , Anne C. Lewin , Alan J. Korman , Mark J. Selby , Changyu Wang , Haichun Huang , Karla A. Henning , Nils Lonberg , Mohan Srinivasan , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Susan Chien-Szu Wong , Huiming Li
IPC: G01N33/566 , G01N33/574 , C07K16/28
Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.029 seconds)
